Combination therapy with pulsed methylprednisolone in rheumatoid arthritis.
نویسندگان
چکیده
منابع مشابه
Combination therapy with pulsed methylprednisolone in rheumatoid arthritis.
Pulsed methylprednisolone (PMP) has been shown to produce clinical improvement and reduction in the ESR and acute phase protein concentrations in patients with active rheumatoid arthritis and has been advocated for use either as an alternative to slow-acting antirheumatoid drugs (SAARDs) or in conjunction with SAARDs to accelerate the response to treatment. To test these potential roles for PMP...
متن کاملCombination therapy with cyclosporin in rheumatoid arthritis.
The role of combination therapy in rheumatoid arthritis (RA) is increasing with the development of new treatment modalities. Past combinations of slow-acting anti-rheumatic drugs resulted in either excessive side-effects or lack of efficacy over single-agent therapy. However, refined methodology and a better understanding of the mechanism of action of newer agents have led to improved combinati...
متن کاملCombination therapy in rheumatoid arthritis.
It has become clear that early suppression of rheumatoid arthritis disease activity is important in preventing progressive joint destruction and functional decline. To achieve this goal, many rheumatologists today advocate a more aggressive approach, using combinations of classic disease-modifying antirheumatic drugs-often including methotrexate-or new drugs. During the last 2 years, the combin...
متن کاملBone metabolism during methylprednisolone pulse therapy in rheumatoid arthritis.
The deleterious effects of corticosteroids (CS) on bone are well known, but probably differ depending on duration and dosage of CS therapy. Presently huge amounts of CS are given over a short period of time in different rheumatic conditions. Not much is known about the effect of this kind of CS treatment on bone metabolism. Twenty patients with persistently active rheumatoid arthritis were trea...
متن کاملCombination second-line therapy for rheumatoid arthritis.
WHILE the treatment of RA has become more aggressive in recent years by the earlier use of second-line agents, remissions, as measured by the ACR [1], resulting from these therapies are rare. Concern has been expressed that the mortality risk in patients with RA is similar to that seen in Stage IV Hodgkin's disease or three vessel coronary artery disease [2]. Certainly, the consideration of dis...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Annals of the Rheumatic Diseases
سال: 1985
ISSN: 0003-4967
DOI: 10.1136/ard.44.11.747